---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-073296"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:42:03.652842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MoonLake raises CEO, CSO, CFO salaries and bonuses citing MIRA trial success

## Summary
- New annual base salaries July 1, 2023: CEO Jorge Santos da Silva CHF 600k (was CHF 450k), CSO Kristian Reich CHF 600k (was CHF 450k), CFO Matthias Bodenstedt CHF 475k (was CHF 325k).
- Target bonuses raised to 55% of salary for CEO and CSO, 50% for CFO (previously 50%, 50%, 40% respectively).
- Board cites positive Phase 2 MIRA trial results and peer benchmarking as rationale for adjustments.

## SEC filing metadata
- accession: 0001213900-23-073296
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/0001213900-23-073296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390023073296/ea184508-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-073296
- JSON: https://secwatch.observer/filing/0001213900-23-073296.json
- Plain text: https://secwatch.observer/filing/0001213900-23-073296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.